Venezuela vs. Colombia vs. Argentina: Comparing Clinical Trial Regulations in Latin America
A side-by-side regulatory comparison of three key LATAM markets — helping sponsors choose the right country for their clinical trial phase and objectives.
August 14, 2026
16
min read
By
bioaccess® Editorial Team
clinical trial regulations comparison
Venezuela vs Colombia clinical trials
INHRR vs INVIMA vs ANMAT
Latin America clinical trial comparison
LATAM regulatory comparison
**Key Takeaways**
- • Venezuela: Lowest costs (40-60% savings), treatment-naïve populations, INHRR regulatory pathway
- • Colombia: Established FIH track record, INVIMA regulatory authority, 16-28 week startup
- • Argentina: ICH member, ANMAT oversight, sophisticated regulatory infrastructure, 20-34 weeks
- • Multi-country: bioaccess® supports trials across all three simultaneously
- • FDA acceptance: Data from all three countries accepted under ICH-GCP
Why compare Venezuela, Colombia, and Argentina?
Venezuela, Colombia, and Argentina represent three distinct but complementary clinical trial markets in Latin America. Each country offers unique advantages, and understanding the regulatory differences helps sponsors make informed decisions about where to conduct their studies.
bioaccess® operates in all three countries and helps sponsors choose the optimal market — or multi-country strategy — based on their therapeutic area, trial phase, budget, and timeline requirements.
Regulatory authorities compared
| Feature | Venezuela | Colombia | Argentina |
|---|---|---|---|
| Regulatory Authority | INHRR | INVIMA | ANMAT/ANEFITS |
| Ministry | MPPS | Min. Health | Min. Health |
| ICH Member | No (follows ICH-GCP) | No (follows ICH-GCP) | Yes (full member) |
| CTA Review Type | Scientific + administrative | Scientific + administrative | Parallel review (ANEFITS) |
| Device Registration | SACS (~20 days) | INVIMA | ANMAT |
| International Recognition | PAHO aligned | PAHO aligned | ICH, IMDRF |
Approval timelines comparison
| Phase | Venezuela | Colombia | Argentina |
|---|---|---|---|
| CRO engagement to CTA submission | 6-10 weeks | 4-8 weeks | 6-10 weeks |
| Regulatory review | 8-16 weeks | 6-12 weeks | 6-8 weeks (ANEFITS) |
| Ethics review | 4-8 weeks (parallel) | 4-6 weeks (parallel) | 6-10 weeks (parallel) |
| Site activation to FPI | 4-6 weeks | 3-5 weeks | 4-6 weeks |
| Total startup | 18-33 weeks | 16-28 weeks | 20-34 weeks |
Cost comparison across the three markets
| Cost Factor | Venezuela | Colombia | Argentina |
|---|---|---|---|
| Per-patient cost (Phase I) | $20K-$40K | $25K-$50K | $30K-$55K |
| Regulatory fees | ~VES 52,612 | ~$3,000-$5,000 USD | ~$2,000-$4,000 USD |
| Site fees (annual) | $30K-$80K | $50K-$120K | $60K-$130K |
| Cost savings vs. US | 40-60% | 30-50% | 30-45% |
| Overall cost ranking | Lowest | Mid-range | Mid-range |
Ethics committee requirements compared
- Venezuela: Institutional ethics committees, PAHO standards, 4-8 week review
- Colombia: INVIMA-supervised institutional ethics committees, 4-6 week review
- Argentina: Provincial ethics committees + ANEFITS parallel review, 6-10 weeks
Which country for which trial phase?
| Trial Phase | Best Fit Country | Why |
|---|---|---|
| First-in-Human (FIH) | Venezuela or Colombia | Lowest cost (VEN), established FIH track record (COL) |
| Early Feasibility Study | Colombia or Argentina | Regulatory familiarity with IDE-like pathways |
| Phase II Proof of Concept | Colombia or Argentina | Larger investigator networks, enrollment speed |
| Phase III Pivotal | Argentina or Colombia | ICH membership (ARG), diverse demographics |
| Market Access / Registration | Venezuela | SACS ~20 day device registration |
Multi-country LATAM strategy
Many sponsors benefit from a multi-country approach that leverages the unique advantages of each market. bioaccess® designs multi-country strategies that may include:
- FIH in Venezuela (lowest cost, treatment-naïve populations)
- Expansion to Colombia for additional enrollment and investigator diversity
- Argentina for ICH-standard regulatory pathway and pivotal trial support
- Multi-country data pooling for stronger FDA submission packages
- Simultaneous regulatory submissions across multiple countries
bioaccess® multi-country advantage
bioaccess® is uniquely positioned to support multi-country clinical trials across Venezuela, Colombia, Argentina, and other LATAM markets. Our single-vendor approach provides:
- Unified project management across all countries
- Harmonized data collection and safety reporting
- Consistent GCP compliance and quality standards
- Single point of contact for sponsors
- Integrated regulatory strategy across multiple authorities
- Cost-efficient multi-country operations
**Need help choosing the right LATAM country?**
Contact bioaccess® for a complimentary country selection assessment based on your protocol and objectives. Or explore our CRO comparison page to see how we stack up.
Frequently asked questions
Get your FIH roadmap for Latin America
bioaccess® helps you choose the right country and strategy for your clinical trial.
Get your FIH roadmap
View case studies